BEA-17
Beyond's analysis on BEA-17
- — Beactica Therapeutics advances novel LSD1-CoREST degrader for glioblastoma into IND-enabling phase
Recent news mentioning BEA-17
- — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
- — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma